Carisma Therapeutics Inc. is a U.S.-based biotechnology company that was built around macrophage engineering for serious diseases such as liver fibrosis and cancer. In its recent filings, the company says it has ceased further development of its lead programs CT-0508 and CT-0525 and does not intend to resume its historical research and development activities. Instead, Carisma is focused on preserving cash, monetizing remaining assets, and pursuing an orderly wind down of operations. The company also has a material strategic transaction context, including the planned OrthoCellix merger described in its 2025 filings.
−300,1 %
−308,6 %
+31,5 %
1.48
1.48
| % | |
|---|---|
| Cell therapy product candidates | 0% Experimental macrophage-engineered therapies and related programs intended for serious diseases such as cancer and liver fibrosis. |
| Research and development services | 0% Internal discovery, preclinical work, and early-stage clinical development activities supporting pipeline advancement. |
| Collaboration and licensing revenue | 100% Revenue recognized from partner arrangements, including the Moderna collaboration and related license accounting. |
| Asset monetization and wind-down activities | 0% Disposition of remaining assets and other non-core activities as the company exits historical operations. |
Carisma does not currently sell commercial products, so it does not have a traditional customer base for approved...
Pharmaceutical or biotech partners that enter research, option, or license agreements to access Carisma's macrophage engineering platform and share development risk.
Companies that may acquire remaining intellectual property, product candidates, or platform rights as Carisma winds down operations.
Investors and transaction partners involved in the OrthoCellix merger and related financing, which are central to the company's near-term corporate strategy.
Patients, physicians, and payors would only become relevant if a product candidate were successfully developed and approved, which the company does not currently expect to resume.
Carisma is headquartered in the United States and its filings are presented as those of a U.S. issuer...
Carisma's stated strategy has shifted away from building a commercial cell therapy company toward conserving cash and...
The company has very limited cash and has explicitly reduced operations to extend runway while it evaluates strategic alternatives.
Management states it will not resume historical R&D and instead aims to sell or otherwise monetize remaining assets in an orderly manner.
The OrthoCellix merger and related financing are central to the company's current strategic path and ownership structure.
Carisma faces acute going-concern and liquidity risk because it has minimal cash, no commercial product revenue, and...
The company has only a small cash balance and states it is pursuing an orderly wind down, with no assurance of stockholder distributions.
The company says the merger may not close and that Carisma holders are expected to own only a small portion of the combined company if it does.
Biotech programs depend on preclinical and clinical success, regulatory review, and manufacturing scale-up, all of which are uncertain and costly.
Management notes low trading volume, broad market volatility, and the possibility of securities class actions after price declines.
: 28.4.2026